Two draft guidances issued together late last month seek to increase both clinical trial efficiency and the amount of information that is available about a drug’s safety and benefits. The two draft guidances address, respectively, adaptive designs and master protocols. This blog post discusses FDA’s recommendations for adaptive designs; master protocols will be addressed in a subsequent blog post.
An adaptive design is a “clinical trial design that allows for prospectively planned modifications to one or more aspects of the design based on the accumulating data from ...
Blog Editors
Recent Updates
- Health Care Without the Hospital: ChatGPT Health and Claude Go Direct to Consumers
- The HTI-5 Proposed Rules: ASTP/ONC’s Cleanup and the Hard Work that Lies Ahead
- Just Released: Telemental Health Laws – Download Our Complimentary Survey and App
- OIG Limits Sign-On Bonuses to In-Home Family Caregivers
- Governing Health AI Development and Adoption: Insights from HHS’s Recently Announced Strategy to Promote AI in Healthcare